Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus TECHNETIUM TC 99M PENTETATE KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus TECHNETIUM TC 99M PENTETATE KIT.
MPI DMSA KIDNEY REAGENT vs TECHNETIUM TC-99M PENTETATE KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Technetium-99m pentetate is a radiopharmaceutical that, after intravenous administration, distributes in the extracellular space and is excreted by glomerular filtration. It is used to assess renal function and for imaging. The Tc-99m label emits gamma rays for detection.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
Intravenous administration of 3-10 mCi (111-370 MBq) for renal imaging in adults. For cerebrospinal fluid (CSF) imaging, 0.5-2 mCi (18.5-74 MBq) intrathecally.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
1.9 hours (terminal elimination half-life). Clinically, effective half-life is ~6 hours due to physical decay of Tc-99m (t½ 6.02 h) combined with biological clearance.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Primarily renal; 90-95% of injected dose excreted unchanged in urine within 24 hours via glomerular filtration. Minimal biliary/fecal elimination (<5%).
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical